PTX-COVID19-B

Providence Therapeutics Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development

Retrieved on: 
Friday, June 2, 2023
Vaccine, Diversified Specialty Institute Holdings, Inc., Partnership, Therapy, Newsweek, Science Policy Research Unit, MBA, Research, Infection, RNA, Messenger, Government, University Health Network, UHN, Hospital, Patient, PTX-COVID19-B, Child, Cancer, Diagnosis, Pharmaceutical industry, Science

This collaboration will allow Providence and UHN to develop mRNA-based vaccines and therapeutics for those living with difficult to treat cancers and infectious diseases, using Providence’s proprietary mRNA platform technology.

Key Points: 
  • This collaboration will allow Providence and UHN to develop mRNA-based vaccines and therapeutics for those living with difficult to treat cancers and infectious diseases, using Providence’s proprietary mRNA platform technology.
  • “This partnership is unique in that it provides country-of-origin rights to Canada for all therapies developed under the agreement.
  • “UHN is world-class, and Providence has demonstrated its mRNA platform is on par with other major mRNA companies.
  • This sets up Canada to be a leader in exporting life-saving therapies throughout the world while taking care of Canadians.”
    Brad Wouters, Executive Vice President, Science and Research at the University Health Network added, “Our partnership with Providence demonstrates the strength of discovery research at the University Health Network and our potential to fuel innovative therapeutic options for patients.

Providence Therapeutics Appoints Robert Georgantas, Ph.D. as President and Chief Technology Officer

Retrieved on: 
Wednesday, February 1, 2023
AbbVie, RNA, Johns Hopkins School of Medicine, MBA, Information Holdings Inc., Immunology, Illinois Institute of Technology, PTX-COVID19-B, GRC, COVID-19, Biomarker, Cancer, Johns Hopkins University, Zeneca, Vaccine, National Center for Advancing Translational Sciences, Therapy, Infection, Providence, Drug discovery, Algorithm, Faculty, RNA transfection, MedImmune, Cell biology, Research, Pharmaceutical industry, Pharmacogenomics

CALGARY, Alberta, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, today announced the appointment of Robert Georgantas III, Ph.D., as President and chief technology officer (CTO).

Key Points: 
  • CALGARY, Alberta, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, today announced the appointment of Robert Georgantas III, Ph.D., as President and chief technology officer (CTO).
  • “Robert’s experience in drug discovery, clinical development, and management at the executive level across several biotech and large pharmaceutical companies will be invaluable as we continue advancing our pipeline of mRNA vaccines,” said Brad Sorenson, MBA, chief executive officer of Providence Therapeutics.
  • He additionally contributed to clinical development and medical affairs activities, participating in the design and statistical analysis of multiple clinical studies.
  • Dr. Georgantas received his Ph.D. at the Johns Hopkins University School of Medicine and his master’s degree in Cellular Biology at the Illinois Institute of Technology.

Providence Therapeutics Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone

Retrieved on: 
Thursday, December 15, 2022
Observation, Government of Canada, Diversified Specialty Institute Holdings, Inc., Partnership, Post-exposure prophylaxis, Government, Cancer, University, Mouse, Vaccine, RNA transfection, Rabies, Public expenditure, Infection, MBA, Public health, Disease, Therapy, Death, COVID-19, Patient, PTX-COVID19-B, Mount Everest

CALGARY, Alberta, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a clinical-stage biotechnology company pioneering mRNA vaccines for infectious diseases and oncology, today announced that its new mRNA vaccine program for rabies post-exposure prophylaxis has achieved a preclinical proof-of-concept milestone. The candidate was developed in partnership with Everest Medicines (“Everest”) utilizing Providence’s clinically validated mRNA technology platform.

Key Points: 
  • CALGARY, Alberta, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a clinical-stage biotechnology company pioneering mRNA vaccines for infectious diseases and oncology, today announced that its new mRNA vaccine program for rabies post-exposure prophylaxis has achieved a preclinical proof-of-concept milestone.
  • “We look forward to continuing to advance our rabies mRNA vaccine program with Everest as a critical part of a growing pipeline of mRNA vaccine candidates for infectious diseases with unmet needs around the world.”
    In a head-to-head immunogenicity comparison study with a commercial inactivated rabies vaccine, mice dosed with Providence’s pre-clinical rabies vaccine candidate produced higher levels of serum neutralizing antibodies than those of mice dosed with the comparator vaccine.
  • Providence and Everest hold 50/50 global rights to develop and commercialize the rabies vaccine.
  • Achieving this preclinical proof-of-concept milestone triggers the execution of a 3,492,365-share transfer of Everest’s publicly traded shares to Providence.

Providence Therapeutics Presents Phase 2 Data on its mRNA COVID-19 Vaccine Candidate PTX-COVID19-B at the 2022 World Vaccine & Immunotherapy Congress

Retrieved on: 
Monday, November 28, 2022
Marketing, COVID-19, Select Committee of the House of Commons on the Civil Government of Canada, Observation, GMT, Therapy, Patient, Cancer, Injection, Government, Seroconversion, University, RNA transfection, Infection, PTX, Immunity, U.S. FDA, Ageing, Kirkbi AG v Ritvik Holdings Inc, Severe acute respiratory syndrome coronavirus 2, Vaccine, Public expenditure, Safety, Pharmaceutical industry, PTX-COVID19-B, Pfizer

This data is a strong scientific and developmental validation of the work that has been accomplished at Providence.

Key Points: 
  • This data is a strong scientific and developmental validation of the work that has been accomplished at Providence.
  • We look forward to initiating a Phase 3 trial in a booster setting following these encouraging safety and immunogenicity results.
  • The presentation highlights positive top-line data from the PRO-CL-002 Phase 2 study evaluating the safety, tolerability and immunogenicity of Providences mRNA COVID-19 vaccine candidate, PTX-COVID19-B.
  • Providence is a Canadian clinical-stage biotechnology company pioneering mRNA therapeutics and vaccines with operations in Calgary, Alberta and Toronto, Ontario.

Providence Therapeutics Appoints Judyanna Yu as Chief Financial Officer

Retrieved on: 
Wednesday, November 2, 2022
RNA transfection, Growth, RNA, Infection, Municipal government in Canada, Government, Cancer, GLOBE, Chartered Professional Accountant, Intention, COVID-19, Public expenditure, COO, Hilltop Holdings Inc., Al-Ameen Arts, Science and Commerce Degree College, Terminology, CFO, Corporate finance, VP, University, Vaccine, Observation, Therapy, Commerce, Patient, KPMG, CPA, Pharmaceutical industry, PTX-COVID19-B

CALGARY, Alberta, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, announces the appointment of Judyanna Yu, CPA, CA as chief financial officer (CFO).

Key Points: 
  • CALGARY, Alberta, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, announces the appointment of Judyanna Yu, CPA, CA as chief financial officer (CFO).
  • Judyannas extensive experience in global finance and operations will be critical as we enter our next phase of growth, said Brad Sorenson, chief executive officer of Providence Therapeutics.
  • Ms. Yu held CFO and VP of Finance roles at several other large private and public companies throughout her career.
  • Providence is a Canadian clinical-stage biotechnology company pioneering mRNA therapeutics and vaccines with operations in Calgary, Alberta and Toronto, Ontario.

Providence Announces Positive Top-Line Data from Phase 2 Primary Immunization Trial of its mRNA Vaccine Candidate PTX-COVID19-B in Adults

Retrieved on: 
Wednesday, October 19, 2022
RNA transfection, Therapy, Observation, PTX, Infection, Select Committee of the House of Commons on the Civil Government of Canada, Vaccine, GMT, Immunity, Severe acute respiratory syndrome coronavirus 2, COVID, U.S. FDA, Patient, AES, Kirkbi AG v Ritvik Holdings Inc, Seroconversion, Cancer, Șaeș, Marketing, Incidence, Intention, University, Safety, Ageing, Injection, GLOBE, Clinical trial, Vaccination, Public expenditure, Government, Terminology, COVID-19, Pharmaceutical industry, PTX-COVID19-B

Based on the positive safety and immunogenicity results, Providence will initiate a Phase 3 trial in a booster setting.

Key Points: 
  • Based on the positive safety and immunogenicity results, Providence will initiate a Phase 3 trial in a booster setting.
  • To our knowledge, this is the first clinical trial directly comparing a candidate vaccine to an approved mRNA vaccine.
  • The PRO-CL-002 Phase 2 study recruited 565 participants aged 18 to 64 years at multiple sites in Canada and South Africa.
  • PTX-COVID19-B is an mRNA vaccine candidate designed to generate potent neutralizing antibodies against the spike protein of SARS-CoV-2 and promote immunity to COVID-19.

Providence Therapeutics Signs Licensing Agreement with SickKids for Immunotargeting Technology

Retrieved on: 
Tuesday, July 12, 2022
Technology, Hospital, MHC, Immunology, Vaccine, Mab, Therapy, Intention, PTX-COVID19-B, ISCB Senior Scientist Award, University, CEO, B cell, COVID-19, RNA transfection, Commercialization, Molecular medicine, Sutro Biopharma, Hospital for Sick Children (Toronto), PI, Antigen, APC, Research, Immune system, Ecosystem, AB, Infection, Pharmaceutical industry, DRS

CALGARY, AB, July 12, 2022 /PRNewswire/ - Providence Therapeutics, Canada's premier mRNA medicines company, is pleased to announce that it has entered into an exclusive licensing agreement with The Hospital for Sick Children (SickKids) of Toronto, ON, for an immunotargeting technology platform.

Key Points: 
  • CALGARY, AB, July 12, 2022 /PRNewswire/ - Providence Therapeutics, Canada's premier mRNA medicines company, is pleased to announce that it has entered into an exclusive licensing agreement with The Hospital for Sick Children (SickKids) of Toronto, ON, for an immunotargeting technology platform.
  • The versatile technology platform can generate both monovalent and multivalent therapeutics, in a varied field of applications, including vaccines.
  • Providence Therapeutics, an emerging specialty Biopharma, has successfully developed a robust, scalable, and effective mRNA medicine platform as exemplified by the clinical success of PTX-COVID19-B.
  • Brad Sorenson, CEO of Providence Therapeutics said, "We are very excited to be working with a prestigious institution like SickKids.

Providence Therapeutics Holdings Inc., VaxThera S.A.S, and the Ministry of Health and Social Protection of the Republic of Colombia, announce the signing of an MOU to explore collaborations for COVID-19 vaccine development

Retrieved on: 
Friday, December 17, 2021
Therapy, China Biologic Products, COVID, Republic, RNA transfection, List of life sciences, Public policy, Company, MOU, PTX-COVID19-B, Industry, Science, COVID-19, Presidential Palace, Chișinău, Vaccine, Intention, CEO, Research, Biotechnology, Safety, Infection, Social protection, IP, Ministry, Pharmaceutical industry, Health, LATAM, AB

The signing took place at a ceremony presided over by President Ivn Duque Mrquez at the Presidential Palace in Bogota.

Key Points: 
  • The signing took place at a ceremony presided over by President Ivn Duque Mrquez at the Presidential Palace in Bogota.
  • The facility in Medellin envisages a R&D center for research into infectious diseases which are especially relevant to the region.
  • Providence is focused on serving the needs of Canada, and other countries that may be underserved by large pharmaceutical programs.
  • The Company seeks to generate health self-sufficiency on the basis of research, development and innovation in biotechnology and healthcare.

Providence Therapeutics announces $2.118 Million USD in funding to support process development and validation of the PTX-COVID19-B program, which targets high quality mRNA COVID-19 vaccine to low-to middle-income countries at affordable prices

Retrieved on: 
Tuesday, December 7, 2021
Bill & Melinda Gates Foundation, AB, Therapy, PTX-COVID19-B, Bill, Safety, Intention, RNA transfection, Vaccine, Foundation, COVID-19, LMIC, Pharmaceutical industry

Additional work supported through this grant is for validation to facilitate the shipping of bulk materials to support regional partnerships in LMIC's that participate in the manufacturing process.

Key Points: 
  • Additional work supported through this grant is for validation to facilitate the shipping of bulk materials to support regional partnerships in LMIC's that participate in the manufacturing process.
  • "With this support from the Bill & Melinda Gates Foundation, we seek to bring our COVID-19 mRNA vaccine to emerging markets at affordable prices.
  • These funds will also empower regional partners to participate in the mRNA vaccine manufacturing process" says Jared Davis, President of Providence Therapeutics.
  • Providence is a leading Canadian clinical stage biotechnology company pioneering mRNA therapeutics and vaccines with operations in Calgary, Alberta and Toronto, Ontario.

Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant

Retrieved on: 
Wednesday, December 1, 2021
Patient, CEO, Safety, CMC, Company, Severe acute respiratory syndrome coronavirus 2, Doctor of Philosophy, Therapy, Vaccine, COVID-19, Degenerative disease, Terminology, RNA transfection, Infection, Intention, PTX-COVID19-B, Pharmaceutical industry

SHANGHAI and CALGARY, Canada, Nov. 30, 2021 /PRNewswire/ -- Everest Medicines and Providence Therapeutics ("Providence") jointly announced today that the companies have started working on a new version of COVID-19 vaccine specifically targeting the new Omicron variant.

Key Points: 
  • SHANGHAI and CALGARY, Canada, Nov. 30, 2021 /PRNewswire/ -- Everest Medicines and Providence Therapeutics ("Providence") jointly announced today that the companies have started working on a new version of COVID-19 vaccine specifically targeting the new Omicron variant.
  • We expect the new Omicron SARS-CoV-2 variant vaccines can be advanced into clinical testing in less than 100 days.
  • "We believe it is essential to develop new vaccines quickly and effectively to combat the new Omicron COVID-19 variant.
  • "We look forward to rapidly developing this new Omicron variant vaccine with Providence, and bringing the benefit of this vaccine to those areas with lower accessibility to current mRNA vaccine treatments in particular."